Stock Data
$1.46 (1.98%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
PTC Therapeutics Inc is a pioneering biopharmaceutical company dedicated to developing innovative medicines for people with rare disorders. With a global presence, it offers treatments for conditions like Duchenne muscular dystrophy, spinal muscular atrophy, and other rare diseases. Its product lineup includes Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi. The company is also advancing research in areas such as Huntington’s disease and amyotrophic lateral sclerosis through its development pipeline. Founded in 1998 and based in South Plainfield, New Jersey, PTC Therapeutics collaborates with leading healthcare organizations to enhance its reach and impact.
PTC Therapeutics crushed Q2 earnings with a 171% EPS beat on blockbuster Sephience revenue that more than doubled sales year-over-year, prompting management to lift full-year product revenue guidance by $100 million. The phenylketonuria therapy generated $151.3 million in Q2 with 1,647 patients on therapy globally, while a $50 million Novartis milestone from the votoplam Huntington's study provided additional lift.
9 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
